Anavex Life Scien…
USUSDAnavex Life Sciences Corp (US:AVXL) — Biotechnology: Biological Products (No Diagnostic Substances). Количество бирж, на которых торгуются акции компании: 2. На этой странице — цена и график, дивиденды, крупнейшие держатели и история количества акций.
О компании
- Сайт
- anavex.com
- Взаимодействие с инвесторами
- anavex.com/investors/
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Штаб-квартира
- NEW YORK, United States
- Генеральный директор
- Terrie Kellmeyer
- Сотрудники
- 34
- Акций в обращении
- 92.7 млн на 2026-08-28
- Свободное обращение
- 89.81 млн
- Рыночная капитализация
- 138.12 млн USD
- Инсайдеры
- 1.71%
- Институциональные инвесторы
- 40.49%
- Отрасль (SIC)
- Biological Products, (No Diagnostic Substances)
- Коэффициент выплат
- 0%
- FCF
- —
- Долг
- 345 USD
- Стаж дивидендов
- —
- Прибыль, FCF и выплаченные дивиденды — за 12 месяцев до 30.06.2026 (последний отчёт компании).
Описание
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Дивиденды
Выплаты дивидендов не обнаружены (проверено 10.10.2026). Компания, вероятно, не выплачивает дивиденды.
Новости этой недели
За последнюю неделю новостей нет. Последняя новость: 24.09.2026.
Крупнейшие держатели
| Держатель | Доля | Акции | Дата отчета |
|---|---|---|---|
| Blackrock Inc. | 8.69% | 8.06 млн | 2026-06-30 |
| Vanguard Capital Managem… | 4.37% | 4.05 млн | 2026-06-30 |
| Two Sigma Investments, L… | 3.29% | 3.05 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.16% | 2.93 млн | 2026-06-30 |
| Geode Capital Management… | 2.6% | 2.41 млн | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.57% | 2.38 млн | 2026-08-31 |
| Federated Hermes MDT Ser… | 2.21% | 2.05 млн | 2026-07-31 |
| State Street Corporation | 2.07% | 1.92 млн | 2026-06-30 |
| MISSLING CHRISTOPHER U (… | ≈1.63% | 1.51 млн | 2025-09-11 |
| Federated Hermes, Inc. | 1.16% | 1.07 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.12% | 1.04 млн | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.08% | 1 млн | 2026-07-31 |
| AQR Capital Management,… | 1.04% | 963 014 | 2026-06-30 |
| Vanguard Portfolio Manag… | 1.02% | 948 633 | 2026-06-30 |
| Summit Financial, LLC | 0.98% | 909 430 | 2026-06-30 |
| Goldman Sachs Group Inc | 0.96% | 890 634 | 2026-06-30 |
| iShares Trust-iShares Ru… | 0.79% | 729 592 | 2026-08-31 |
| iShares Trust-iShares Bi… | 0.72% | 667 442 | 2026-08-31 |
| VANGUARD SCOTTSDALE FUND… | 0.49% | 450 282 | 2026-05-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.47% | 440 209 | 2026-05-31 |
| iShares Trust-iShares Mi… | 0.34% | 312 610 | 2026-08-31 |
| THOMAS STEFFEN PHD (Dire… | ≈0.05% | 43 651 | 2025-06-05 |
